| rivastigmine / Generic mfg. |
2005-004909-29: Satunnaistettu, kaksoissokkoutettu, lumekontrolloitu yhdessä keskuksessa toteutettu tutkimus rinnakkaisilla ryhmillä rivastigmiinin vaikutuksesta MS-tautiin liittyvän fatiikin aivomekanismeihin |
|
|
| Ongoing | 4 | 32 | Europe | Exelon 3,0 mg, Exelon 3,0 mg | Juhani Ruutiainen | Multippeliskleroosia sairastavat potilaat ja terveet vapaaehtoiset kontrollihenkilöt. | | | | |
2006-004435-30: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients. |
|
|
| Ongoing | 4 | 12 | Europe | EXELON 56CPS 1,5MG, EXELON 56CPS 1,5MG | FONDAZIONE SANTA LUCIA | Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8 | | | | |
2017-000569-61: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial |
|
|
| Not yet recruiting | 4 | 1205 | Europe | Donepezil, Galantamine, Rivastigmine, Donepezil, N06DA04, N06DA03, Coated tablet, Prolonged-release capsule, Capsule, ARICEPT, REMINYL, RIVASTIGMINE | CHU de Bordeaux, DGOS PHRC N 2016 | Alzheimer disease Maladie d'Alzheimer, Diagnosis of probable or possible AD, defined according to the NINCDS-ARDRA criteria cMild to moderate stage, defined by a MMSE score above 15 at the time of pré-inclusion Nouveau cas de Maladie d'AlzheimerDiagnostic de MA probable ou possible définie selon les critères NINCDS-ARDRA, Diseases [C] - Nervous System Diseases [C10] | | | | |
ChiCTR2100052254: Research on the Intervention Effect of Western Medicine on Preclinical AD: a Randomized Controlled Trial. |
|
|
| Recruiting | 4 | 192 | | Take 971 Targeting Aβ Manno-oligosaccharide Diacid Capsules orally ;Take rivastigmine orally ;Take placebo group orally | Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, The National Key Research and Development Project of China (grant number 2018YFC1315204) | Alzheimer's disease | | | | |
| Recruiting | 4 | 10000 | | Rivastigmine Bitartrate Tablets | Beijing Yuanxin Technology Group Co., Ltd.; Wanquan Wante Pharmaceutical Jiangsu Co., Ltd., Wanquan Wante Pharmaceutical Jiangsu Co., Ltd. | Alzheimer's disease and dementia | | | | |
NCT02670161: Quality Improvement and Practice Based Research in Neurology Using the EMR |
|
|
| Enrolling by invitation | 4 | 3300 | NA | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description), (too many characters to list in this field; see Intervention Description) | NorthShore University HealthSystem | Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke | 12/25 | 12/26 | | |
NCT03454646: Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) |
|
|
| Not yet recruiting | 4 | 1205 | Europe | cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) | University Hospital, Bordeaux | Alzheimer Disease, Cholinesterase Inhibitors | 04/27 | 09/27 | | |
